Variable number tandem repeats (VNTRs) as modifiers of breast cancer risk in carriers of BRCA1 185delAG.
Journal
European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
01
06
2022
accepted:
08
11
2022
revised:
10
10
2022
pmc-release:
01
02
2024
pubmed:
27
11
2022
medline:
10
2
2023
entrez:
26
11
2022
Statut:
ppublish
Résumé
Despite substantial efforts in identifying both rare and common variants affecting disease risk, in the majority of diseases, a large proportion of unexplained genetic risk remains. We propose that variable number tandem repeats (VNTRs) may explain a proportion of the missing genetic risk. Herein, in a pilot study with a retrospective cohort design, we tested whether VNTRs are causal modifiers of breast cancer risk in 347 female carriers of the BRCA1 185delAG pathogenic variant, an important group given their high risk of developing breast cancer. We performed targeted-capture to sequence VNTRs, called genotypes with adVNTR, tested the association of VNTRs and breast cancer risk using Cox regression models, and estimated the effect size using a retrospective likelihood approach. Of 303 VNTRs that passed quality control checks, 4 VNTRs were significantly associated with risk to develop breast cancer at false discovery rate [FDR] < 0.05 and an additional 4 VNTRs had FDR < 0.25. After determining the specific risk alleles, there was a significantly earlier age at diagnosis of breast cancer in carriers of the risk alleles compared to those without the risk alleles for seven of eight VNTRs. One example is a VNTR in exon 2 of LINC01973 with a per-allele hazard ratio of 1.58 (1.07-2.33) and 5.28 (2.79-9.99) for the homozygous risk-allele genotype. Results from this first systematic study of VNTRs demonstrate that VNTRs may explain a proportion of the unexplained genetic risk for breast cancer.
Identifiants
pubmed: 36434258
doi: 10.1038/s41431-022-01238-z
pii: 10.1038/s41431-022-01238-z
pmc: PMC9905572
doi:
Substances chimiques
BRCA1 protein, human
0
BRCA1 Protein
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
216-222Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM114362
Pays : United States
Organisme : NHGRI NIH HHS
ID : R01 HG010149
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Organisme : NHGRI NIH HHS
ID : RM1 HG011558
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to European Society of Human Genetics.
Références
Carcinogenesis. 2008 Jun;29(6):1197-201
pubmed: 18413362
Nat Genet. 2010 Oct;42(10):885-92
pubmed: 20852631
Am J Hum Genet. 1999 May;64(5):1371-7
pubmed: 10205268
Mol Med Rep. 2018 Sep;18(3):3490-3496
pubmed: 30066865
JAMA. 2015 Apr 7;313(13):1347-61
pubmed: 25849179
Genome Res. 2018 Nov;28(11):1709-1719
pubmed: 30352806
Transl Psychiatry. 2021 May 21;11(1):306
pubmed: 34021117
Med Oncol. 2014 Apr;31(4):885
pubmed: 24615008
J Med Genet. 2008 Jul;45(7):425-31
pubmed: 18413374
Biometrics. 1992 Jun;48(2):361-72
pubmed: 1637966
Genet Med. 2020 Oct;22(10):1653-1666
pubmed: 32665703
Nat Genet. 2017 Dec;49(12):1767-1778
pubmed: 29058716
PLoS One. 2011;6(9):e25632
pubmed: 21980511
Behav Brain Funct. 2005 Aug 31;1:15
pubmed: 16131404
Genet Epidemiol. 2012 Apr;36(3):274-91
pubmed: 22714938
Mol Psychiatry. 2017 Jul;22(7):944-953
pubmed: 28289284
Breast Cancer Res Treat. 2008 Oct;111(3):475-80
pubmed: 18030615
Onco Targets Ther. 2015 Aug 13;8:2111-20
pubmed: 26316780
Mol Biol Rep. 2022 Feb;49(2):895-905
pubmed: 35040008
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Breast Cancer Res. 2014 Dec 31;16(6):3416
pubmed: 25919761
PLoS One. 2013;8(2):e56055
pubmed: 23409121
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Br J Cancer. 2007 Jan 15;96(1):11-5
pubmed: 17213823
Cancer Sci. 2012 Jun;103(6):1121-8
pubmed: 22404099
PLoS One. 2011 Apr 27;6(4):e19119
pubmed: 21589638
Nucleic Acids Res. 1999 Jan 15;27(2):573-80
pubmed: 9862982
Oncotarget. 2017 Jun 27;8(26):42116-42124
pubmed: 28178669
Nat Genet. 2019 Nov;51(11):1652-1659
pubmed: 31676866
Oncotarget. 2017 Apr 25;8(17):28021-28027
pubmed: 28427205
Genomics. 2013 May;101(5):273-81
pubmed: 23517681
Nat Commun. 2021 Feb 17;12(1):1078
pubmed: 33597508
Ann Oncol. 2018 May 1;29(5):1292-1303
pubmed: 29509840
Nat Commun. 2020 Sep 15;11(1):4637
pubmed: 32934226
Breast Cancer Res. 2007;9(2):104
pubmed: 17466083
Cancer Genomics Proteomics. 2008 Sep-Oct;5(5):241-51
pubmed: 19129555
Nat Genet. 2016 Jan;48(1):22-9
pubmed: 26642241
Am J Hum Genet. 2018 Sep 6;103(3):421-430
pubmed: 30100087
Schizophr Res. 2007 Nov;96(1-3):100-11
pubmed: 17766091
J Mol Biol. 2021 Sep 17;433(19):167184
pubmed: 34364876
N Engl J Med. 1993 Aug 19;329(8):517-23
pubmed: 8336750
Acta Neuropathol. 2018 Jun;135(6):827-837
pubmed: 29589097
Future Oncol. 2013 Nov;9(11):1623-36
pubmed: 24156323
Genome Biol. 2011;12(1):R1
pubmed: 21205303
Mol Neurobiol. 2014 Dec;50(3):757-64
pubmed: 24643655
Am J Hum Genet. 2008 Apr;82(4):937-48
pubmed: 18355772
Endocr Relat Cancer. 2016 Oct;23(10):T69-84
pubmed: 27528622
Breast Cancer Res Treat. 2011 Jul;128(2):467-72
pubmed: 21221763
Nucleic Acids Res. 2016 May 5;44(8):3750-62
pubmed: 27060133
Nat Commun. 2021 Apr 6;12(1):2075
pubmed: 33824302
Am J Hum Genet. 2021 May 6;108(5):764-785
pubmed: 33811808
PLoS Genet. 2013;9(3):e1003212
pubmed: 23544013
Nat Genet. 1996 Oct;14(2):185-7
pubmed: 8841191
J Natl Cancer Inst. 2017 Jul 1;109(7):
pubmed: 28376175